Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 28, 2018 16:30 ET | Source: Alimera Sciences, Inc.

Alimera Sciences Reports Fourth Quarter and Full Year 2017 Financial Results

GAAP Net Loss cut by 34% from $33.2 in 2016 to $22.0 million in 2017Adjusted EBITDA loss reduced by 61% from $22.8 million in 2016 to $8.8 million 2017Filed for Type II variation for uveitis in Europe...
February 27, 2018 07:30 ET | Source: Alimera Sciences, Inc.

Alimera Sciences to Present at the 38th Annual Cowen & Co. Health Care Conference

ATLANTA, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today...
February 14, 2018 07:30 ET | Source: Alimera Sciences, Inc.

Alimera Sciences to Report Fourth Quarter and Full Year 2017 Results on February 28, 2018

ATLANTA, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Alimera Sciences (NASDAQ:ALIM), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it will...
January 08, 2018 07:30 ET | Source: Alimera Sciences, Inc.

Alimera Sciences Refinances Debt With New $40 Million Debt Facility From Solar Capital

ATLANTA, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription...
January 04, 2018 07:30 ET | Source: Alimera Sciences, Inc.

Alimera Sciences Receives Acceptance of Filing to Obtain Approval for ILUVIEN® Non-Infectious Posterior Uveitis Indication in Europe

ATLANTA, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today...
December 11, 2017 07:30 ET | Source: Alimera Sciences, Inc.

Alimera Sciences Announces Patients Now Being Treated With ILUVIEN® In Ireland

ATLANTA, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today...
November 08, 2017 07:30 ET | Source: Alimera Sciences, Inc.

Alimera Sciences Announces Nine iluvien® data sets to be Presented at 2017 american academy of ophthalmology

ATLANTA, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today...
November 07, 2017 07:30 ET | Source: Alimera Sciences, Inc.

Alimera Sciences' CEO Dan Myers to Present During Ophthalmology Innovation Summit at American Academy of Ophthalmology 2017

ATLANTA, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today...
November 01, 2017 17:37 ET | Source: Alimera Sciences, Inc.

Alimera Sciences Reports Third Quarter 2017 Financial Results

Net Revenue of $9.8 million for the third quarter of 2017 compared to $8.3 million for the third quarter of 2016, an 18% increaseGAAP Net Loss of $5.3 million for the third quarter of 2017 compared to...
October 25, 2017 13:30 ET | Source: Alimera Sciences, Inc.

Alimera Sciences to Report Third Quarter 2017 Results November 1st, 2017

ATLANTA, Oct. 25, 2017 (GLOBE NEWSWIRE) -- Alimera Sciences (NASDAQ:ALIM), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it will...